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Introduction
 Apoptosis plays a crucial role in cancer cell 
elimination.  However, the apoptotic process has 
not been fully elucidated. Understanding its 
molecular mechanisms should provide insights 
into the treatment and prevention of cancer1–5. 
Rac, a member of the Rho family of small GTP-
binding proteins, has been implicated in transduc-
ing a number of signals for various biological pro-
cesses6–9.  Upon stimulation by growth factors, Rac 
induces a variety of important cellular processes, 
including endogenous superoxide generation, 
cytoskeletal organization, gene expression, cell 
cycle progression, vesicle trafﬁcking, cell-to-cell 
and cell-to-extracellular-matrix adhesions, and 
malignant transformation10–12.  Furthermore, Rac 
is often overexpressed in most human cancers, 
such as colon, breast, lung, myeloma, and head 
and neck squamous cell carcinoma13–17 and upreg-
ulation of Rac provides a survival signal that is 
known to protect several cancer cell lines and 
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Abstract : Apoptosis is one mechanism by which cancer cells can be eliminated.  Therefore, under-
standing the signaling pathways that transduce apoptotic signals in cancer cells is an indispens-
able component of cancer research.  Rac, a member of the Rho family of proteins, has been impli-
cated in the regulation of cell survival and apoptosis.  However, the mechanisms underlying this 
process remain to be elucidated.  To understand the role of Rac in oral squamous cancer, we inhib-
ited its activity by a Rac-speciﬁc small molecule inhibitor, NSC23766, or transfection of dominant 
negative Rac (Rac-DN), and discovered that inhibition of Rac activity elicits apoptosis in highly 
malignant oral squamous carcinoma (OSC-19) cells.  Upon suppression of Rac, we observed up-reg-
ulation of c-Jun N-terminal kinase (JNK), leading to caspase-dependent apoptosis.  Furthermore, 
stimulation of protein phosphatase (PP5) rescued apoptosis caused by Rac inhibition by dephospho-
rylating JNK.  Taken together, inhibition of Rac activity leads to the suppression of PP5 activity, 
which results in extensive activation of JNK and caspase-dependent apoptosis.  In conclusion, Rac 
inhibition may represent a novel therapeutic approach for oral squamous carcinoma.
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transformed ﬁbroblasts from apoptosis18–21.  How-
ever, the precise mechanisms by which the Rac 
pathway transduces survival signals that inhibit 
apoptosis remain to be elucidated.  Understanding 
the molecular basis of Rac-mediated cell survival 
and apoptosis may lead to strategies to improve 
anti-cancer therapies.
 JNK, a member of the mitogen-activated protein 
kinase (MAPK) superfamily22, is a key regulator of 
many cellular events, including apoptosis.  It has 
recently been reported that Rac suppresses the 
JNK signaling pathway23 ; caspase-dependent 
apoptosis is due to the activation of JNK24,25. 
Therefore, it is important to understand the mech-
anisms underlying the regulation of JNK by Rac.
 PP5, a member of the Ser/Thr phosphatase fam-
ily, can dephosphorylate and inactivate JNK26. 
PP5 is unique among the Ser/Thr phosphatases in 
that it possesses three tetratricopeptide repeat 
(TPR) motifs in its N terminus that serve as pro-
tein-protein interaction domains27, which has 
recently been reported as a positive effector of Rac 
signaling28.  PP5 is also stimulated in the presence 
of arachidonic acid29, which is not the case for 
other Ser/Thr phosphatases such as PP1, PP2A, 
PP2B, and PP2C. 
 In this report, we describe the role of Rac in 
highly malignant oral squamous carcinoma 
(OSC-19) cells. 
Materials and Methods 
1. Reagents and antibodies
 All chemicals were purchased from Calbiochem 
unless otherwise stated.  Polyclonal antibody to 
cleaved caspase-3 was purchased from Cell Signal-
ing Technology.  The anti-JNK and phospho-JNK 
(Thr183/Tyr185) polyclonal antibodies were pur-
chased from R&D Systems.  The anti-Rac1 and 
PP5 monoclonal antibodies were obtained from 
Upstate Biotechnology and BD Biosciences, 
respectively.  Secondary antibodies were all from 
Cell Signaling Technology.  The cDNA of N17Rac1 
(Rac-DN), with a mutation of amino acid 17 from 
Thr to Asn, was provided by Dr A.  Hall (University 
College London, London, UK).  Expression plas-
mid was constructed as described elsewhere10.
2. Cell culture and treatment
 OSC-19 cells were previously established from a 
metastatic tumor in a cervical lymph node of a 
patient with grade-4C (cordlike type) SCC of the 
tongue.  Fibroblasts were obtained from the 
patient's lip skin.  Cells were cultured in Dulbec-
co's modiﬁed Eagle's medium supplemented with 
10% calf serum, 5% Nu-serum (Collaborative 
Research Inc., Bedford, MA, USA), and 2 mM 
L-glutamine in a humidiﬁed atmosphere of 5% 
CO2 at 37℃, and then routinely passed when 
85–90% conﬂuent.  Unless otherwise stated, cells 
were seeded in 6-well plates with 2 ml growth 
medium and were treated on the next day.  Inhibi-
tors were added an hour before NSC23766 treat-
ment and cells were incubated for a further 9 h. 
The concentration of DMSO in the controls was 
equal to the concentration of DMSO in inhibitor-
containing media and never exceeded 0.1%.
 OSC-19 cells were transiently transfected with 
the expression plasmids described above using the 
FuGENE HD Transfection Reagent (Roche 
Applied Science).  The transfection was performed 
according to the manufacturer's instructions.
 
3.  Rac pull-down assay and Western blot 
analysis
 The Rac pull-down assay was performed as fol-
lows. Brieﬂy, OSC-19 cells and ﬁbroblasts were 
incubated for 9 h with or without 100 μM 
NSC23766 in the presence of serum.  Subse-
quently, OSC-19 cells were transiently transfected 
with Rac-DN for 48 h.  Both cells were mixed with 
0.3 ml lysis buffer (25 mM Tris pH 7.5, 150 mM 
NaCl, 5 mM MgCl2, 1% NP-40, 1 mM DTT, 5% 
glycerol) and incubated at 4℃ for 5 min.  Lysates 
were clariﬁed, the protein concentrations normal-
ized, and GTP-loaded Rac was pulled down from 
total protein lysates with a Rac1 Activation Kit 
using GST-human Pak1-PBD (Pierce) according to 
the manufacturer's instructions.  Washed precipi-
tates were boiled, subjected to SDS-PAGE, trans-
ferred onto nitrocellulose membranes and quanti-
ﬁed by anti-Rac1 immunoblotting.  Western blot 
analysis was conducted as follows.  Cell extracts 
were prepared by lysing cells with a RIPA Lysis 
Buffer (Santa Cruz Biotechnology).  Lysates were 
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clariﬁed, protein concentrations normalized, and 
the remaining supernatant was boiled in 3×
sample buffer.  The same amount of samples was 
resolved by SDS-PAGE and transferred onto nitro-
cellulose membranes.  After incubation of the 
membranes with the appropriate antibodies, spe-
ciﬁc bands were visualized using ECL (Amersham 
Biosciences).
4. Immunoﬂuorescence
 DAPI staining of nuclei was performed to detect 
morphological changes.  Brieﬂy, 105 OSC-19 cells 
or ﬁbroblasts were seeded on an 18-mm round 
glass coverslip in a 12-well plate.  Following treat-
ment as described in Results, the cells were ﬁxed 
in 4% paraformaldehyde.  The cells were then 
washed and incubated with DAPI for 1 h at room 
temperature.  After washing, the coverslips were 
adhered to glass slides in mounting medium.  Flu-
orescent images were captured using an Axiovert 
200M (Zeiss, Germany).
5. Detection of apoptosis
 Apoptosis was monitored by using Cell Death 
Detection ELISA (Roche Applied Science), which is 
based on a quantitative sandwich enzyme immu-
noassay principle using mouse monoclonal anti-
bodies against DNA and histone to detect internu-
cleosomal fragmented DNA.  The assay was 
performed according to the manufacturer's 
instructions.
Results and Discussion
 In this report, we describe a novel mechanism 
by which suppression of Rac activity elicits cas-
pase-dependent apoptotic cell death in highly 
malignant oral squamous carcinoma cells.  We 
found that (1) the inhibition of Rac-mediated sig-
naling leads to the caspase-dependent apoptosis of 
OSC-19 cells but not of ﬁbroblasts ; (2) increased 
JNK signaling is associated with suppression of 
Rac activity and ultimately results in caspase-
dependent apoptosis ; (3) PP5 activity is reduced 
by Rac inhibition, leading to increased JNK activ-
ity and JNK-mediated apoptosis.  Therefore, Rac 
may represent an ideal therapeutic target for the 
treatment of oral squamous carcinoma because, at 
least in vitro, inhibition of Rac selectively triggers 
apoptosis of cancer cells but not normal cells.  A 
schematic representation of the mechanisms of 
apoptosis induced by inhibition of Rac activity in 
OSC-19 cells is shown in Fig. 1.
Fig. 1　Schematic representation of mechanisms of apoptosis induced by inhibition of Rac activity in OSC-19 cells.
Suppression of Rac activity (treated with NSC23766) results in extensive activation of JNK and leads to caspase-dependent apop-
tosis in Oral Squamous carcinoma cells. Moreover, PP5 (affected by arachidonic acid) may suppress JNK activity through a direct 
interaction, although other mediators of JNK activity might exist.
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1.  Inhibition of Rac activity induces caspase-
dependent apoptosis in OSC-19 cells but 
not in ﬁbroblasts
 To test the hypothesis that because Rac activity 
is increased in a number of cancers its inhibition 
might be detrimental to tumor cells, we ﬁrst 
examined the effects of a Rac-speciﬁc small mole-
cule inhibitor, NSC23766 (30), on OSC-19 cells. 
Interestingly, cells treated with NSC23766 showed 
cell death in a dose-dependent manner (Fig. 2A), 
Fig. 2 Inhibition of Rac using a Rac-speciﬁc small molecule inhibitor, NSC23766, induces cell death in OSC-19 cells, but 
not in ﬁbroblasts. (A) Phase-contrast pictures of OSC-19 cells and ﬁbroblasts treated with NSC23766. Cells were 
grown in 10% calf serum and 5% Nu-serum in the presence or absence of NSC23766 (50 or 100 μM) for 24 h. 
Cells were grown under the same conditions in the presence or absence of NSC23766 (50 or 100 μM) for 24 h. (B) 
Rac pull-down assay. OSC-19 cells were cultured with or without NSC23766 (100 μM) for 9 h or transiently 
transfected with Rac-DN. Fibroblasts were treated with NSC23766 (100 μM) for 9 h. Cell lysates were then sub-
jected to Rac pull-down assay using GST-human Pak1-PBD, followed by Western blotting with anti-Rac mAb. 
The results shown are representative of three independent experiments. (C) DAPI staining of nuclei to detect 
morphological changes. OSC-19 cells were seeded on coverslips and incubated with or without NSC23766 (50 or 
100 μM) for 9 h or transiently transfected with Rac-DN. Fibroblasts were treated with NSC23766 (100 μM) for 9 
h under the same conditions. The cells were ﬁxed and stained with DAPI to visualize nuclear morphological 
changes. (D) Cell death ELISA. OSC-19 cells were cultured with or without NSC23766 (50 or 100 μM) for 9 h or 
transiently transfected with Rac-DN. Fibroblasts were treated with NSC23766 (100 μM) for 9 h. Cells were mon-
itored using Cell Death Detection ELISA according to the manufacturer's instructions. The data are expressed as 
mean ± SD of three independent experiments. (E) Western blot analysis of cleaved caspase-3. OSC-19 cells were 
cultured with or without NSC23766 (50 or 100 μM) for 9 h or transiently transfected with Rac-DN. Cell lysates 
were then Western blotted with anti-cleaved caspase-3 pAb. The results shown are representative of three inde-
pendent experiments.
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while ﬁbroblasts treated with NSC23766 failed to 
undergo cell death (Fig. 2A).  To investigate any 
differences in Rac activity between OSC-19 cells 
and ﬁbroblasts, Western blot analysis of total Rac 
and a Rac effector domain pull-down assay were 
conducted.  Rac was overexpressed in OSC-19 
cells under all conditions, and the Rac pulled-
down from OSC-19 cells was more active than 
that from ﬁbroblasts under untreated conditions, 
suggesting that Rac may be more highly expressed 
and activated in OSC-19 cells than in ﬁbroblasts 
(Fig. 2B).  A decrease in Rac activity was observed 
in both cell types following treatment with 
NSC23766.  Therefore, to determine whether the 
suppression of Rac activity by NSC23766 resulted 
in cell death by necrosis or apoptosis, we exam-
ined NSC23766-treated DAPI-stained cells by 
microscopy, and found dose-dependent nuclear 
condensation and fragmentation, which are char-
acteristics of apoptosis (Fig. 2C).  This was not 
observed in ﬁbroblasts treated with NSC23766 for 
the same period of time (Fig. 2C).  To conﬁrm 
apoptotic cell death, we performed a cell death 
ELISA assay (Fig. 2D), which showed a signiﬁcant 
2- to 6-fold increase in apoptosis in treated 
OSC-19 cells compared with control cells or ﬁbro-
blasts.  These ﬁndings demonstrate that the inhi-
bition of Rac activity by NSC23766 induced apop-
tosis in OSC-19 cells.  Furthermore, to conﬁrm 
this interpretation, we investigated the effects of 
inhibiting Rac activity by expression of a myc-
tagged dominant negative mutant of Rac (Rac-
DN).  Cells transfected with an expression vector 
encoding Rac-DN showed nuclear condensation 
and fragmentation (Fig. 2C), and cell death ELISA 
conﬁrmed apoptosis (Fig. 2D).  The amount of 
apoptosis observed seemed less with Rac-DN than 
with NSC23766, which seems reasonable because 
the transfection efﬁciency was approximately 
30–40% and a small amount of Rac activity was 
observed in pull-down assays from cells tran-
siently expressing Rac-DN (Fig. 2B).  Taken 
together, these data show that down-regulation of 
Rac activity causes apoptotic cell death in OSC-19 
cells but not in normal ﬁbroblasts. 
 Caspase activation is critical for initiation of 
apoptotic cell death31.  Therefore, we next exam-
ined whether the effects of Rac on apoptosis can 
be attributed to activation of caspases.  Western 
blot analysis of OSC-19 cells treated with 
NSC23766 showed that caspase-3 was cleaved in a 
dose-dependent manner (Fig. 2E).  Cleaved cas-
pase-3 was also detected in cells transfected with 
Rac-DN, although at slightly lower levels, consis-
tent with the analysis of apoptosis above and sug-
gesting that this apoptotic cell death is caspase-
dependent (Fig. 2E).  Taken together, these data 
demonstrate that suppression of Rac activity 
results in caspase-dependent apoptosis in OSC-19 
cells.
 The mechanism by which suppression of Rac 
activity causes apoptosis in oral squamous carci-
noma cells may be unique.  In this report, we show 
that suppression of Rac resulted in apoptosis in 
OSC-19 cells.  Other highly malignant oral 
squamous carcinoma cells, such as HOC-313 cells, 
which are classiﬁed as grade-4D by mode of inva-
sion, also undergo caspase-dependent apoptosis 
upon NSC23766 treatment and transient Rac-DN 
transfection, although to a lesser extent than 
OSC-19 cells (data not shown).  In contrast, ﬁbro-
blasts do not undergo apoptosis under the same 
conditions.  In addition, Madin-Darby canine kid-
ney (MDCK) epithelial cells did not undergo 
observable apoptosis, even when treated with 
NSC23766 (data not shown).  Consistent with pre-
vious reports13–17, Rac expression and activity 
were elevated in OSC-19 cells relative to ﬁbro-
blasts ; therefore, high Rac activity might be nec-
essary for cancer progression and maintenance of 
the cancer cell phenotype.  It is possible that 
interfering with this high activity might lead to 
termination of cancer cells by apoptosis.
2.  Hyper-phosphorylation of JNK is neces-
sary and sufﬁcient for the effects of Rac 
on apoptosis and not associated with acti-
vation of ASK1 upon Rac suppression
 To study the mechanism underlying Rac-inhib-
ited apoptosis in OSC-19 cells, we determined the 
pathway downstream of Rac signaling.  Recent 
ﬁndings have indicated that caspase-dependent 
apoptosis is due to the activation of JNK24,25,32.  It 
has recently been reported that Rac can suppress 
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the JNK pathway23.  Therefore, to determine 
whether regulation of JNK is connected with the 
effects of Rac on apoptosis, we inhibited Rac and 
examined the phosphorylation of JNK.  In cells 
treated with NSC23766, we observed hyper-phos-
phorylation of JNK as shown in Fig. 3A.  Hyper-
phosphorylation of JNK did not result from 
increased expression, as the total protein level 
was similar to that in control cells (Fig. 3A).  Simi-
lar results were observed in cells treated with 
NSC23766 for 3 and 6 h, although apoptosis 
detected by cell death ELISA was not seen at 
these time points, indicating that prolonged acti-
vation of JNK may be required for initiation of 
apoptosis in OSC-19 cells (data not shown).  Fibro-
blasts treated with NSC23766 under the same 
conditions showed no change in JNK activity (Fig. 
3A).  Next, to determine whether the effects of Rac 
on apoptosis are mediated through up-regulation 
of JNK activity, we evaluated the effects of the 
Fig. 3 Hyper-phosphorylation of JNK is necessary and sufﬁcient for apoptosis induced by inhibition of Rac. (A) 
Western blot analysis of JNK and pJNK. OSC-19 cells were cultured with or without NSC23766 (50 or 100 μ
M) for 9 h. Fibroblasts were treated with NSC23766 (100 μM) for 9 h. Cell lysates were Western blotted with 
anti-JNK and pJNK pAbs. The results shown are representative of three independent experiments. (B) 
Phase-contrast pictures and DAPI staining of nuclei to detect morphological changes. OSC-19 cells were pre-
treated with SP600125 (20 μM for 1 h) and treated with NSC23766 (100 μM for 24 h). OSC-19 cells were 
seeded on coverslips, pretreated with SP600125 (20 μM for 1 h) and treated with NSC23766 (100 μM for 9 h). 
The cells were ﬁxed and stained with DAPI to visualize nuclear morphological changes. As a control, OSC-19 
cells were incubated in medium containing DMSO for the same period of time. (C) Cell death ELISA and 
Western blot analysis of JNK and pJNK. OSC-19 cells were pretreated with SP600125 (20 μM for 1 h) and 
treated with NSC23766 (100 μM for 9 h). Cells were monitored using the Cell Death Detection ELISA ac-
cording to the manufacturer's instructions. As controls, OSC-19 cells were incubated in medium containing 
DMSO, SP600125 (20 μM), for the same period of time. Data are expressed as mean ± SD of three indepen-
dent experiments. Cell lysates were Western blotted with anti-JNK and pJNK pAbs. The results shown are 
representative of three independent experiments. (D) Western blot analysis of cleaved caspase-3. OSC-19 
cells were pretreated with SP600125 (20 μM for 1 h) and were treated with NSC23766 (100 μM for 9 h). Cell 
lysates were Western blotted with anti-cleaved caspase-3 pAb. The results shown are representative of three 
independent experiments.
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JNK-speciﬁc inhibitor SP60012533 on apoptosis 
elicited by NSC23766. OSC-19 cells pretreated 
with SP600125 prior to NSC23766 treatment did 
not undergo cell death (Fig. 3B).  Treatment with 
SP600125 prevented nuclear condensation and 
fragmentation, and cell death ELISA showed that 
apoptosis was decreased by approximately 50% 
(Fig. 3B and C).  To demonstrate the involvement 
of caspases, Western blot analysis of cells pre-
incubated with SP600125 was performed. 
Cleaved caspase-3 was not observed following pre-
treatment of SP600125, supporting the ﬁnding 
that inhibition of Rac leads to apoptosis through 
JNK activation (Fig. 3D).  Taken together, these 
data indicate that prolonged activation of JNK is 
necessary and sufﬁcient for caspase-dependent 
apoptosis following Rac inhibition in OSC-19 cells. 
One difference downstream of Rac between cancer 
cells and normal cells is the regulation of JNK 
activity following Rac inhibition.  As reported 
here, we observed that hyper-phosphorylation of 
JNK was induced by suppression of Rac in OSC-19 
cells but not in ﬁbroblasts.  In addition, speciﬁc 
suppression of JNK activity with a small molecule 
inhibitor rescued the effects of Rac inhibition on 
apoptosis.  Similar hyper-phosphorylation of JNK 
and caspase-dependent apoptosis following inhibi-
tion of Rac activity were observed in a second type 
of oral squamous carcinoma cells, HOC 313 (data 
not shown).  Apoptosis was not observed at early 
time points after treatment, even though JNK was 
activated at these times (data not shown) ; these 
results indicate that prolonged activation of JNK 
may be required for initiation of apoptosis in oral 
squamous carcinoma cells.  Taken together, these 
ﬁndings suggest that prolonged activation of JNK 
is necessary and sufﬁcient to trigger apoptotic cell 
death in OSC-19 cells when Rac activity is sup-
pressed.
3.  Activation of PP5 dephosphorylates JNK 
and suppresses the effects of Rac on apop-
tosis
 How does Rac regulate JNK activity in OSC-19 
cells?  Because hyper-phosphorylation of JNK is a 
key step in apoptosis following Rac inhibition, it is 
possible that Rac signaling negatively regulates 
JNK activity through a protein phosphatase, pre-
venting OSC-19 cells from undergoing apoptosis. 
Although numerous protein phosphatases can 
dephosphorylate and inactivate JNK26, PP5, a 
member of the Ser/Thr phosphatase family, is a 
candidate to down-regulate JNK activity because 
it contains three TPR protein-protein interaction 
motifs27 and has recently been shown to interact 
with and serve as a positive effector of Rac28.  It 
has also been reported that the catalytic activity 
of PP5 is activated in vitro by arachidonic acid29, 
which does not occur in other Ser/Thr phos-
phatases such as PP1, PP2A, PP2B, and PP2C. 
Therefore, it was postulated that activation of PP5 
with arachidonic acid might lead to dephosphory-
lation of JNK and turn off an apoptotic switch 
triggered by Rac inhibition in OSC-19 cells.  To 
evaluate this hypothesis, we tested whether PP5 
activation by arachidonic acid would rescue apop-
totic cell death following Rac inhibition.  As shown 
in Fig. 4A, cell death was not observed in cells 
pretreated with arachidonic acid following incuba-
tion with NSC23766.  Cells were incubated in the 
presence of arachidonic acid, then treated with 
NSC23766, and examined for nuclear morphology 
changes.  Interestingly, cells pretreated with 
arachidonic acid showed no features of apoptosis 
and cell death ELISA showed a significant 
decrease in apoptosis relative to cells that were 
not pretreated (Fig. 4A and B).  Furthermore, 
cleaved caspase-3 was suppressed to control levels 
by arachidonic acid pretreatment, indicating that 
PP5 may play a crucial role in rescuing apoptosis 
triggered by inhibition of Rac in OSC-19 cells (Fig. 
4C).  To further conﬁrm the regulation of JNK 
activity through PP5, the phosphorylation state of 
JNK under the same conditions was examined by 
Western blot analysis.  Pretreatment of cells with 
arachidonic acid markedly reduced JNK phospho-
rylation in comparison to control cells, strongly 
suggesting that PP5 regulates the phosphoryla-
tion state of JNK (Fig. 4D).  The reduction in JNK 
activity was not due to increased PP5 expression, 
as PP5 protein levels were similar in treated and 
control cells (Fig. 4D).  These results indicate that 
the regulation of JNK activity may be regulated 
by Rac through PP5 in OSC-19 cells. 
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Conclusions
 Our studies demonstrate that suppression of 
Rac activity results in extensive activation of JNK 
and leads to caspase-dependent apoptosis in 
OSC-19 cells.  Moreover, our ﬁndings suggest that 
PP5 may suppress JNK activity through an inter-
action, although other mediators of JNK activity 
might exist.  Therefore, further studies will be 
directed toward understanding the signal trans-
duction pathways responsible for modulation of 
apoptosis by inhibition of Rac and may ultimately 
lead to the development of new therapeutic 
approaches for the treatment of oral squamous 
carcinoma.
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